Adverse drug reactions and Alzheimer disease;Iatrogénie et maladie d'Alzheimer

Revue de Medecine Interne

Volumn 30, Issue SUPPL. 4, 2009, Pages

  Piau, A ^a   Nourhashemi, F ^a,b   Vellas, B ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Adverse drug reactions; Alzheimer disease

Indexed keywords

CHOLINE ACETYLTRANSFERASE INHIBITOR; MEMANTINE; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG SURVEILLANCE PROGRAM; HUMAN; PRESCRIPTION; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IATROGENIC DISEASE; MEDICATION ERRORS; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 70849136025     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.09.012     Document Type: Article

References (79)

1. Swift C.G. The clinical pharmacology of ageing. Br J Clin Pharmacol 56 3 (2003) 249-253
2. Bouvenot G., and Villani P. Apport des essais pré-AMM à la connaissance du risque iatrogène chez la personne âgée. Therapie 59 2 (2004) 233-236
3. Loke Y.K., and Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol 1 1 (2001) 3
4. Pirmohamed M., James S., Meakin S., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 329 7456 (2004) 15-19
5. EMIR : effets indésirables des médicaments : incidence et risque, sur les hospitalisations liées à un effet indésirable médicamenteux. Coordination CRPV de Bordeaux 12. [non publié].
6. Beijer H.J., and de Blaey C.J. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 24 2 (2002) 46-54
7. Fauchais A.L., Ploquin I., Ly K., et al. Iatrogénie chez le sujet âgé de plus de 75 ans dans un service de posturgences. Étude prospective de cohorte avec suivi à six mois. Rev Med Interne 27 (2006) 375-381
8. Handler S.M., Wright R.M., Ruby C.M., and Hanlon J.T. Epidemiology of medication-related adverse events in nursing homes. Am J Geriatr Pharmacother. 4 3 (2006) 264-272
9. Laroche M.L., Charmes J.P., Nouaille Y., et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly?. Br J Clin Pharmacol. 63 2 (2007) 177-186
10. Nourhashémi F., Andrieu S., Sastres N., et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 15 (2001) 21-25
11. Granjon C., Beyens M.N., Frederico D., et al. Existe-t-il un sur-risque d'accidents médicamenteux chez les sujets âgés atteins de troubles cognitifs ? À propos de 82 déments hospitalisés. Neurol Psychiatr Geriatr 6 (2006) 21-28
12. Hanlon J.T., Schmader K.E., Ruby C.M., and Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 49 (2001) 200-209
13. Legrain S. Consommation médicamenteuse chez le sujet âgé : consommation, prescription, iatrogénie et observance. Synthèse bibliographique programme PMSA. HAS, 2005.
14. Budnitz D.S., Shehab N., Kegler S.R., et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 147 (2007) 755-765
15. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 157 (1997) 1531-1536
16. Afssaps. Prévenir la iatrogenèse médicamenteuse chez le sujet âgé. Mise au point. 2005.
17. Parminder R. et al. Effectiveness of cholinesterase inhibitors and memantine fort treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008; 148:379-397.
18. Bordier P., Garrigue S., Lanusse S., et al. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. CNS Drugs. 20 5 (2006) 411-417
19. Nelson M.W., and Buchanan R.W. Galantamine-induced QTc prolongation. J Clin Psychiatry. 67 1 (2006) 166-167
20. Bordier P., Lanusse S., Garrigue S., et al. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging. 22 8 (2005) 687-694
21. Fisher A.A., and Davis M.W. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother. 42 2 (2008) 278-283
22. Gill S.S., Anderson G.M., Fischer H.D., et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 169 9 (2009) 867-873
23. Tavassoli N., Sommet A., Lapeyre-Mestre M., et al. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal British National Formulary). Drug Saf. 30 11 (2007) 1063-1071
24. Haute Autorité de santé. Commission de la transparence. Avis du 26 novembre 2008.
25. EMEA « rapporteur type II variation assessment report Axura°/Ebixa° » 26 septembre 2008. Lettre à Prescrire le 6 mars 2009.
26. FDA « Approval labeling text Namenda° » 16 octobre 2003. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021487lbl.pdf. Consulté en septembre 2009.
27. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006) 1525-1538
28. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005) 596-608
29. Ballard C.G., Gauthier S., Cummings J.L., et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 5 5 (2009) 245-255
30. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 (2006) 191-210
31. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebocontrolled trials. JAMA 294 (2005) 1934-1943
32. Wang P.S., Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 (2005) 2335-2341
33. Haute Autorité de santé. Limiter la prescription de psychotropes chez la personne âgée confuse agitée et chez le patient Alzheimer présentant des troubles du comportement perturbateurs. Communiqué de Presse. 8 juillet 2009.
34. Glass J., Lanctôt K.L., Herrmann N., et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 331 7526 (2005) 1169
35. Turner E.H., Matthews A.M., Linardatos E., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 358 3 (2008) 252-260
36. Kirsch I., Deacon B.J., Huedo-Medina T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med. 5 2 (2008) e45
37. Barbui C., Esposito E., and Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 180 (2009) 291-297
38. Cipriani A., Barbiui C., and Geddes J.R. Suicide, depression and antidepressants. BMJ 330 (2005) 373-374
39. Gurwitz J.H., Avorn J., et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 161 (2001) 1629-1634
40. Tinetti M.E. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 348 1 (2003) 42-49
41. Hien le T.T., Cumming R.G., Cameron I.D., et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 53 (2005) 1290-1295
42. Thapa P.B., Gideon P., Cost T.W., Milam A.B., and Ray W.A. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 339 (1998) 875-882
43. Hartikainen S., Lönnroos E., and Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci. 62 10 (2007) 1172-1181
44. Souchet E., Lapeyre-Mestre M., and Montastruc J.L. Drug related falls: a study in the French Pharmacovigilance database. Pharmacoepidemiol Drug Saf. 14 1 (2005) 11-16
45. Leipzig R.M., Cumming R.G., and Tinetti M.E. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 47 1 (1999) 30-39
46. Ray W.A., Thapa P.B., and Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 48 (2000) 682-685
47. Ensrud K.E., Blackwell T., Mangione C.M., et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 163 8 (2003) 949-957
48. Duplantier C., Courtat-Bailly B., Moreau C., et al. Syncopes et lipothymies d'origine iatrogène. Ann Cardiol Angeiol (Paris) 53 (2004) 320-324
49. Leipzig R.M., Cumming R.G., and Tinetti M.E. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc. 47 1 (1999) 40-50
50. Gage B.F., Birman-Deych E., Kerzner R., et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 108 (2005) 612-617
51. Feil D.G., MacLean C., and Sultzer D. Quality indicators for the care of dementia in vulnerable elders. J Am Geriatr Soc. 55 Suppl. 2 (2007) S293-301
52. Mattson R.H., and Cognitive. affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis. 1 Suppl. 1 (2004) S10-S17
53. Meador K.J., Loring D.W., Hulihan J.F., et al. Differential cognitive and behavioral effects of topiramate and valproate. Neurology. 60 9 (2003) 1483-1488
54. Lechevallier-Michel N., Molimard M., Dartigues J.F., et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol. 59 2 (2005) 143-151
55. Mulsant B.H., Pollock B.G., Kirshner M., et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 60 (2003) 198-203
56. Ancelin M.L., Artero S., Portet F., et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 332 7539 (2006) 455-459
57. Mayers A.G., and Baldwin D.S. Antidepressants and their effect on sleep. Hum Psychopharmacol 20 (2005) 533-559
58. Stage K.B., and Kragh-Sorensen P.B. Age-related adverse drug reactions to clomipramine. Acta Psychiatr Scand 105 (2002) 55-59
59. Pollock B.G. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 60 Suppl. 20 (1999) 4-8
60. Pezzella G., Moslinger-Gehmayr R., and Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70 (2001) 1-10
61. Lopez-Ibor J.J., and Conesa A. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Curr Med Res Opin 20 (2004) 855-860
62. Van Amerongen A.P., Ferrey G., and Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord 72 (2002) 21-31
63. Mottram P., Wilson K., and Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 1 (2006) CD003491
64. Horak F., and Stubner U.P. Comparative tolerability of second generation antihistamines. Drug Saf 20 (1999) 385-401
65. Herbison P., Hay-Smith J., Ellis G., and Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 326 7394 (2003) 841-844
66. Gill S.S., Mamdani M., Naglie G., et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 165 (2005) 808-813
67. Deakin J.B., Rahman S., Nestor P.J., Hodges J.R., and Sahakian B.J. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomised controlled trial. Psychopharmacology 172 (2004) 400-408
68. Gray S.L., Lai K.V., and Larson E.B. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf. 21 2 (1999) 101-122
69. Moore A.R., and O'Keeffe S.T. Drug-induced cognitive impairment in the elderly. Drugs Aging. 15 1 (1999) 15-28
70. Favrelière S., Lafay-Chebassier C., Alkhidir F., et al. Drug-induced dementia: a case/non-case study in the French Pharmacovigilance database. Therapie. 62 6 (2007) 507-511
71. Hanlon J.T., Horner R.D., Schmader K.E., et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 64 (1998) 684-692
72. Paterniti S., Dufouil C., and Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study. J Clin Psychopharmacol 22 (2002) 285-293
73. Lagnaoui R., Begaud B., Moore N., et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 55 (2002) 314-318
74. Hulse G.K., Lauthenschlager N.T., Tait R.J., and Almeida O.P. Dementia associated with alcohol and other drug use. Int Psychogeriatr 17 (2005) S109-2. 7
75. Madhusoodanan S., and Bogunovic O.J. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 3 5 (2004) 485-493
76. Mintzer M.Z., and Griffiths R.R. Triazolam and zolpidem: effects on memory and attentional processes. Psychopharmacology 144 (1999) 8-19
77. Berlin I., Warot D., Hergueta T., Molinier P., Bagot C., and Puech A.J. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 13 (1993) 100-106
78. Hemmeter U., Muller M., Bischof R., Annen B., and Holsboer-Trachsler E. Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology 147 (2000) 384-396
79. Verdoux H., Lagnaoui R., and Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 35 (2005) 307-315